Liver transplantation for the Budd-Chiari syndrome.
A retrospective study was performed that analyzed 23 patients who had an orthotopic liver transplantation for the Budd-Chiari syndrome with end-stage liver disease. Patient follow-up was as long as 14 years. The technical considerations relevant to the Budd-Chiari syndrome were discussed. There have been no serious complications of postoperative anticoagulation. Three patients, all of whom died, had recurrence of the Budd-Chiari syndrome. No other patient has had evidence of recurrent Budd-Chiari syndrome on postoperative liver biopsies. One-, 3-, and 5-year actuarial survival was 68.8%, 44.7%, and 44.7%, respectively. It was concluded that orthotopic liver transplantation is the most effective treatment for patients with the Budd-Chiari syndrome and end-stage liver disease.
Halff
G
G
Department of Surgery, University Health Center of Pittsburgh, University of Pittsburgh, Pennsylvania.
Todo
S
S
Tzakis
A G
AG
Gordon
R D
RD
Starzl
T E
TE
D000293:Adolescent; D000328:Adult; D006502:Budd-Chiari Syndrome / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D002423:Cause of Death; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D008099:Liver / Q000473:pathology; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology; D011517:Prothrombin Time; D012008:Recurrence; D012189:Retrospective Studies; D013162:Splenic Vein; D013927:Thrombosis / Q000453:epidemiology